Indeed, activation of a cGAS-STING-mediated immune response has been shown to predict response to neoadjuvant chemotherapy in early breast cancer [44], and conversely the suppression of the cGAS-STING pathway is associated with trastuzumab resistant breast cancer [45]. Here, STING1 is linked to breast cancer.